

1 **The Functional Communication Checklist for People Living with** 2 **Primary Progressive Aphasia: Study Protocol**

3
4 Jeanne Gallée¹, PhD; Jade Cartwright², PhD; Maya L Henry³, PhD; Aimee Mooney⁴,
5 MS; Brielle C Stark⁵, PhD; Anna Volkmer⁶, PhD; Connie Nakano¹, MPH; Rob J
6 Fredericksen⁷, PhD; Kimiko Domoto-Reilly⁸, MD, MS; Paul K Crane¹, MD, MPH

7
8
9
10 ¹Department of Medicine, University of Washington, Seattle, WA, United States of
11 America

12 ²School of Health Sciences, University of Tasmania, Launceston, Australia

13 ³Department of Speech, Language, and Hearing Sciences, University of Texas-Austin,
14 Austin, TX, United States of America

15 ⁴Department of Neurology, Oregon Health & Science University, Portland, OR, United
16 States of America

17 ⁵Department of Speech, Language, and Hearing Sciences, Indiana University,
18 Bloomington, IN, United States of America

19 ⁶Division of Psychology and Language Sciences, University College London, London,
20 United Kingdom

21 ⁷Department of Allergy and Infectious Diseases, University of Washington, Seattle, WA,
22 United States of America

23 ⁸Department of Neurology, University of Washington, Seattle, WA, United States of
24 America

25
26
27 Corresponding Author: Jeanne Gallée, BA, PhD

28 Department of Medicine

29 University of Washington

30 Harborview Medical Center

31 325 9th Avenue

32 Seattle, WA 98104

33 United States of America

34 Phone: +1 (425)-246-5579

35 Email: jgallee@uw.edu

36
37
38 **Keywords:** assessment; functional communication; primary progressive aphasia; person-
39 centered

43 **Abstract**

44 This study protocol describes the development of the first instrument of functional
45 communication for people living with primary progressive aphasia (PPA), with future
46 applications to other progressive conditions, with expert validation, item-level reliability
47 analyses, and stakeholder input and outcomes. Progressive conditions like PPA require
48 monitoring, and as such, re-assessment. Re-assessment poses the high risk of being
49 burdensome, destructive, and of little use to the patient. As such, there is a significant
50 need to establish a validated and reliable measure that (1) poses minimal patient burden
51 and (2) captures communication ability in a strengths-based manner that is representative
52 of daily communication needs and challenges. A strengths-based approach to assessment
53 is widely recognized as the optimal way to promote patient autonomy, minimize harm,
54 and implement functional treatment protocols and strategies. To date, there are no
55 strengths-based assessment tools that were developed for people living with PPA. This
56 study protocol describes our work to address this gap in clinical practice and research.

57

58

59

60

61

62

63

64

65

66 **1 Introduction**

67 Fifty thousand Americans are currently estimated to be living with primary
68 progressive aphasia (PPA) [1], a clinical syndrome that initially presents with focal
69 language decline and is typically attributable to pathological findings consistent with
70 frontotemporal degeneration or Alzheimer’s disease (AD) [2-5]. People living with PPA
71 (PwPPA) experience progressive decline in focal aspects of speech, language, and
72 communication in the mild to moderate stages [2-5]. To date, there are three PPA variants
73 established in the literature: the nonfluent/agrammatic, semantic, and logopenic with
74 differentiated syndromic characteristics (see Table 1) [2-5].

75 To receive a PPA diagnosis, a person must experience prominent difficulty with
76 speech and language at symptom onset that is the principal source of disrupted
77 functioning and that is attributable to neurodegenerative disease [2-4]. PPA causes
78 important changes in functional communication (FC), which is defined as the
79 “transactional success” of expression [6], and which is a fundamental feature of human
80 connection [7]. FC ability in PPA diverges by variant, individual differences, and time
81 [5,8-10]. A person-centered approach—a holistic and humanistic method that promotes
82 the autonomy and needs of the patient—is integral to establish how individual differences
83 can impact a person’s success in FC [9,11] and to deliver individualized care [9,12].

84

85 PPA is a devastating, but relatively rare, condition [1]. As a result, a “gold
86 standard” approach to care remains to be established [8]. Clinical assessment is essential
87 to accurately identify and to formulate a specific diagnosis of PPA, and efficiently lead to
88 treatment recommendations and post-diagnostic supports; however, to date, assessment
89 procedures and documentation protocols are non-standardized or non-specific to this
90 population [8,11]. These significant limitations have adverse effects on the accuracy and
91 efficiency of diagnostic formulation and assessment outcomes, and result in irregularities
92 in clinical evaluation protocols and cross-institutional characterization of research
93 cohorts.

94 **Table 1. The Primary Symptoms of the Established PPA Variants.**

Variant	Primary Symptoms at Onset¹⁻⁵
Nonfluent/agrammatic	Impaired motor speech planning and syntax
Semantic	Loss of object knowledge, confrontation naming, and single-word comprehension
Logopenic	Anomia and reduced repetition ability

95 Particularly for rare neurodegenerative conditions, accurate and efficient
96 assessment is critical to formulate a diagnosis, establish the effects of intervention, and
97 monitor decline [8,11,13,14]. There is a need for direct assessment of functional
98 communication (FC) in people with dementia [15] and PwPPA [16], particularly as this
99 skill relates to early detection and designing optimal plans for intervention [13]. Early
100 detection and treatment approaches also rely upon the identification of and distinction
101 between the variant-specific impact on FC. Therefore, we have set out to develop a

102 standardized checklist for FC, and in this paper present our protocol for this project. This
103 study protocol centers on advancing assessment practices of FC for PPA, a critically
104 important aspect of supporting activities of daily living, autonomy, and therapeutic
105 intervention [7]. FC is interactive and contextual [7], yet traditional assessments of
106 speech and language are not interactive and do not generalize to natural conversation
107 [11,17]. As such, the current inventory of tools developed to capture and characterize FC
108 decline in PPA is insufficient [8,16,17].

109 Therefore, the aim of this project is to create and validate an interactive tool to
110 capture clinically relevant aspects of FC for people living any of the three variants of
111 PPA (PwPPA). The primary outcome of this work will be the FC Checklist (FCC), a
112 novel instrument to capture and track strengths-based change in FC ability. The FCC's
113 quantitative outcomes for speech, language, and communication performance create a
114 common language that allows for cross-domain comparisons and consistency across
115 evaluators and sites. The FCC will enable clinicians to quantify FC in a systematic and
116 trackable manner and make appropriate and justified therapeutic recommendations [18].
117 The FCC will also serve as a research tool, providing more nuanced insight into the
118 trajectory of a person's cognitive-linguistic performance and impact on overall
119 functioning, with the opportunity to provide participants with meaningful research
120 outcomes. Moreover, clinicians and researchers will be able to use the FCC as a tool to
121 provide valuable information to patients, care partners, and other providers to understand
122 and actively engage with plans of care [14,19,20].

123 While some screening tools have been developed (e.g., the *Mini Linguistic State*
124 *Examination*) [21], traditional aphasia instruments lack sensitivity to detect mild or early-

125 stage PPA and fail to holistically evaluate FC ability [22]. Effective FC may be verbal,
126 text-based, non-verbal, or multimodal [7]; however, few existing assessment tools
127 examine non-verbal communication and instead focus on the other modalities in
128 isolation. These tools thus fail to examine multimodal interaction—a crucial feature of
129 day-to-day FC [22]. As such, there is a critical need for holistic, multimodal, and
130 sensitive measures of FC ability, spanning clinical observation, quantification, and
131 patient self- report [9,12].

132 We plan to develop a reliable tool that can be used over time and across
133 institutions and providers. There is an important tool in this space, the Progressive
134 Aphasia Severity Scale (PASS) [23]. The PASS was developed to capture decline across
135 domains of speech, language, and communication in PPA. While the PASS provides a
136 robust means of tracking change across an impressive range of linguistic domains, the
137 PASS’s measurement of FC is restricted to a single item and is impairment-focused.
138 Impairment-focused assessments are restrictive in that impairments are unreliable
139 predictors of a person’s functional success [18,20,24]. In contrast, employing a strengths-
140 based and person-centered approach reframes the patient as an active agent in their life
141 [24] by capitalizing on their capabilities and their role in daily functioning
142 [7,8,11,24,25]—a critical shift that is necessary to enhance the individualized and
143 operationalized impact of clinical care. Finally, PwPPA report that most assessment
144 protocols are time consuming and burdensome [11,14,25]. Minimizing assessment
145 burden for people living with neurodegenerative conditions, such as PPA, is crucial to
146 maintain trust and deliver respectful and patient-oriented care [11,14,25]. As such, there

147 is a significant need for a person-centered, strengths-based, and minimally taxing
148 measure of FC. We propose that the FCC will meet this need.

149

150 **2 Materials and Methods**

151 **2.1 Study Objectives**

- 152 1. Tool Development: curate an expert-validated clinical assessment tool of FC for
153 PwPPA.
- 154 2. Tool Implementation: establish interrater reliability and validation of quantified
155 scores of FC.

156

<insert Figure 1>

157

Figure 1. Study Flow.

158 **2.2 Ethics Approval**

159 Approval for the study entitled “Assessment of Communicative Ability in
160 Alzheimer’s Disease and Related Dementias” (STUDY00019344) was granted by the
161 University of Washington’s Internal Review Board (IRB) on January 2nd, 2024.

162 **2.3 Tool Development**

163 **2.3.1 Participants**

164 At least fifty speech-language pathologist (SLP) experts will be identified and
165 recruited through the International SLT/P PPA Network
166 (<https://speechtherapypa.builtbyknights.com/>) as well as through a PubMed search for
167 researchers with recent publications on FC in adults with neurodegenerative conditions.

168 **2.3.2 Experimental Approach**

169 The purpose of the FCC is to broadly address whether specific features of speech,
170 language, and nonverbal communication present as strengths or interferences in FC. To
171 meet this purpose, item selection for the FCC will be guided by the methodological
172 framework proposed by Kirshner & Guyatt (1985) [18]. As a conduit for appropriate
173 clinical recommendations, which includes referral to speech and language services, the
174 FCC must be an index that is (1) discriminatory [18], to distinguish people with and
175 without FC challenges and (2) evaluative [18], to facilitate a level of sensitivity that
176 captures change longitudinally in speech, language, and non-verbal communication. To
177 ensure that the FCC meets the primary purpose in the context of this year-long award, we
178 will use an electronic Delphi consensus process [26-28], consistent with the CREDES
179 best practices [26] and technical recommendations [27,28] (see prototype generated in
180 Phase One in Table 2 and Figure 1, Phases 3 and 4). The Delphi procedure is a structured
181 technique to form consensus using collective intelligence [26-28]. To conform to
182 standards, the procedure must be (1) anonymous, (2) able to actively engage a panel of
183 experts, (3) iterative, and (4) able to provide feedback in the form of response summaries
184 after each round [26-28]. The anonymity of web-enabled Delphi processes reduces
185 pressure to conform to group opinion [26-28].

186 Delphi processes have three distinct stages. The first is *conceptualization* [26],
187 which entails defining the research goals, Delphi format, candidate FCC items, and
188 additional questions for panelists. This stage (as described in Phase One, Tool
189 Development in Figure 1) was conducted between February 21st and March 10th, 2024
190 and carried out by the panel of PPA experts (JG, JC, MLH, AM, BCS, and AV). The

191 second and third stages entail data collection and analysis (Phases 2 through 4, Tool
192 Development in Figure 1). For this proposal, in Phase 2 of Tool Development, at least 50
193 PPA and/or FC experts from around the world will be invited to participate in iterative
194 rounds of an online Qualtrics^{XM} [29] survey to establish rank order and rationales for the
195 inclusion of each of the FCC items. Expert selection will be guided by the
196 epistemological approach offered by Mauksch et al. (2020) [30], with a focus on panelist
197 familiarity and expertise. In each round, participants will be asked to rank existing FCC
198 items based on their clinical relevance and provide additional or alternative items to best
199 evaluate FC in PPA. Participants will also be given the opportunity to explain their
200 rationales and feedback for each FCC item. To minimize individual and collective bias,
201 the survey introduction will draw explicit attention to possible biases [28]. Phases 3 and 4
202 of Tool Development will occur iteratively until closing criteria have been met (see
203 below).

204 **2.3.3 Statistical Analysis**

205 We will implement a mixed-methods approach of qualitative and quantitative
206 analyses to evaluate panelist feedback. Panelists will receive aggregate descriptive
207 outcomes of rank order and general inclusionary/exclusionary rationale after each round,
208 as well as summaries of qualitative suggestions for additional or alternative items. This
209 feedback will explain item ranking per FCC constituent and the resulting modification of
210 the checklist items. Closing criteria will consist of a minimum of 80% consensus for
211 inclusion of FCC items [26-28] with statistical stability (insignificant difference in item
212 consensus) over the minimum of four rounds [26] of the survey. Following the final
213 round of the Delphi procedure, panelists will receive the comprehensive statistical

214 analyses and results. Investigator JG and Co-Investigators PKC and RJF will code the
215 qualitative feedback by content type (e.g., rank order rationale, rationale for proposed
216 alternative/revised item, etc.) using Dedoose qualitative coding software [31] with
217 acceptable interrater reliability of 80% or higher [28].

218 We will then utilize a qualitative “memo-ing” process based on the Grounded
219 Theory model of qualitative inquiry [32] to summarize themes within each content type.
220 Investigator JG and Co-Investigators PKC and RJF will independently summarize themes
221 and subsequently meet to discuss and reconcile differences in interpretation and achieve
222 consensus. For descriptive statistics, arithmetic mean values and standard deviations will
223 be calculated. Interquartile ranges will be used to assess consensus. Bipolarity analyses
224 will be conducted to examine whether there are sub-group differences despite in-group
225 consensus. Finally, outlier analyses will be conducted to detect whether there are
226 differential interpretations of certain items due to statement comprehensibility or other
227 reasons revealed in the qualitative feedback.

228 **2.4 Tool Implementation**

229 **2.4.1 Participants**

230 2.4.1.1 SLPs

231 After the FCC has been finalized by meeting closing criteria of the Delphi
232 procedure, 15 SLPs who were not involved in developing the FCC and who have
233 specialization in PPA will be recruited to pilot the checklist to rate FC based on the
234 discourse samples from video recordings described below (see section 2.4.1.2 Video
235 Curation). Expert SLPs will be recruited through the International SLT/P PPA Network
236 [33], which has a reach of upwards of a hundred of relevant experts available to be

237 recruited for this purpose. Additionally, non-expert SLPs who work with adult
238 populations will be recruited through online forums and the University of Washington.
239 Participants will receive a one-time payment of \$100 for their participation in Phase 2 of
240 Tool Implementation.

241 2.4.1.2 PwPPA

242 We will recruit individuals that span the PPA spectrum, with three to four
243 examples of each of the three established variants [2], including heterogeneous profiles
244 [4,5], and five age-matched controls with typical cognition. The purpose of the control
245 group is to anchor the typical range of variability of communication. Participants will be
246 recruited from the University of Washington's Alzheimer's Disease Reach Center (UW
247 ADRC) and affiliated Memory and Brain Wellness Center. Numbers of unimpaired
248 participants are surpassed by the active cohorts of the UW ADRC's Clinical Core and
249 Registry. Eligible and interested participants will be consented to participate in an
250 identifiable video recording. Participants will receive a one-time payment of \$150 for
251 their participation in the assessment described in Phase 1, Tool Implementation.

252 **2.4.2 Experimental Approach**

253 2.4.2.1 Video Curation

254 Video recordings will be collected of PwPPA and controls using a procedure
255 consistent with the validation process described for the *Clinical Dementia Rating*
256 (CDR®), a global staging scale of individual domains [34,35]. The assessments will
257 consist of three naturalistic discourse samples, elicited by a conversational in-take to
258 establish the PwPPA's self-described strengths and needs, and one closed-ended and one
259 open-ended discourse prompt prior to completing the *Quick Aphasia Battery* (QAB) [36]

260 to establish performance across domains of articulation, auditory comprehension, lexical
261 retrieval, motor function, reading, repetition, and semantic processing. Patient-reported
262 outcome measures will be gathered by asking PwPPA to rate the relative difficulty of the
263 discourse sample tasks using an aphasia-friendly, stakeholder-approved 5-point visual
264 scale (0 = high burden, 4 = no burden) from the freely available, psychometrically
265 evaluated *Aphasia Impact Questionnaire-concise* (AIQ-concise) [37]. The AIQ-concise
266 scale offers a selection of gender and race visualizations to allow PwPPA to choose the
267 pictorial representations that closest align with their visualizations of self. Patient ratings
268 of perceived task-burden for the discourse tasks will be compared to those of the
269 comprehensive QAB to establish whether discourse-based tasks are perceived as less
270 burdensome.

271 2.4.2.2 FCC Implementation

272 In separate 45-minute online Zoom calls, the 15 SLPs will watch the participant
273 responses to the open and closed-ended discourse prompts. Following each case example,
274 the SLPs will be asked to fill out the FCC via a Qualtrics^{XM} [29] poll. SLPs will be asked
275 to simultaneously record their thought processes as they carefully consider the
276 applicability of each FCC item, consistent with the “Think Aloud” protocol [32,38,39].
277 Application of the “Think Aloud” protocol will result in the collection of qualitative
278 targeted thinking to further refine the FCC. Two additional questions will be asked: (1)
279 How effective is this person’s communication (1 = very effective, 5 = acceptable, 10 =
280 ineffective) and (2) Rate the level of impairment of FC (0 = typical, 0.5 = questionable, 1
281 = mild, 2 = moderate, 3 = severe). The latter question maps onto the PASS’s “Functional
282 Communication” item [23], whereas the former allows for a “big picture” rating and how

283 this relates to the survey’s other items. Following the completion of these Zoom calls,
284 results will be analyzed for item-level inter-rater reliability. Agreement between the
285 participant samples and “gold standard” ratings for each case example, generated by the
286 study team and expert panelist consensus, will also be analyzed.

287 We will then gather targeted feedback for the people assessed, providing the
288 person and people who want to communicate with them specific and evidence-based
289 recommendations to address areas of concern and improve FC. To generate this targeted
290 feedback [9,11,12,25] based on the FCC’s structure, the study team will develop
291 informational guidance and clinical recommendations for each of the behaviors included.
292 The purpose is multifold and intended for patients, care partners, researchers, and
293 clinicians. In the context of a Zoom-based focus group, study team members will
294 generate concrete descriptions and guidance to address the possible interference posed by
295 each behavior described in the FCC (e.g., “word form” or “rate”, see Table 2)
296 accompanied by publicly available and aphasia-friendly visuals [40]. Consistent with the
297 best practice principles for PPA [8] and expert recommendations, the feedback template
298 will explain the purpose of the discourse tasks collected in Phase 1, Tool Implementation,
299 contextualize the communication behavior outcomes, and provide tailored
300 recommendations to enhance FC. The feedback template will be made publicly available
301 online through the UW ADRC website for anyone to input FCC outcomes and receive
302 individualized guidance for strengths and relative interferences.

303

304 **Table 2. Prototype of the Functional Communication Checklist established in Phase**
 305 **1 in preparation for the anonymous Delphi Consensus process to be conducted in**
 306 **Phases 2 through 4.**

Functional Communication Checklist (Prototype, Version 1.5, 03/04/2024)				
COMMUNICATION CONSTITUENT	Interference Level			NONE
	Mild	Moderate	Severe	
SPEECH (motor function and other acoustic properties that contribute to form)				
Voice/Resonance (breathiness/breath support, loudness)	1	2	3	<input type="checkbox"/>
Articulatory precision (clarity of target speech sounds; speech distortions)	1	2	3	<input type="checkbox"/>
Word form accuracy (do the words have speech sound errors?)	1	2	3	<input type="checkbox"/>
Word production (absence of false starts and perseverations)	1	2	3	<input type="checkbox"/>
Flow (absence of significant pausing)	1	2	3	<input type="checkbox"/>
Prosody (use of pitch, phrase boundaries, and lexical stress)	1	2	3	<input type="checkbox"/>
Rate of speech (appropriateness of speech tempo, i.e., not too fast or too slow)	1	2	3	<input type="checkbox"/>
TOTAL				
Observed Strengths:				
<i>Clinician-observed:</i>				
<i>Patient-reported:</i>				
LANGUAGE (linguistic content: specificity, task relevance, and comprehension)				
Specificity of word retrieval (does the speaker use underspecified/vague/empty language or specific/meaningful to refer to target words or concepts)	1	2	3	<input type="checkbox"/>
Semantic accuracy (accuracy or appropriateness of word choice as it relates to meaning)	1	2	3	<input type="checkbox"/>
Syntactic complexity (relative complexity of phrases in terms of type and length)	1	2	3	<input type="checkbox"/>
Informativeness/topic completeness (does the speaker's point come across?)	1	2	3	<input type="checkbox"/>

Circumlocution (does the speaker successfully speak around a topic or find alternative methods to describe them?)	1	2	3	<input type="checkbox"/>
Comprehension of single words (concepts or actions)	1	2	3	<input type="checkbox"/>
Comprehension of phrase-level output (statements, commands, or questions)	1	2	3	<input type="checkbox"/>
TOTAL				
Clinician-observed:				
Patient-reported:				
DISCOURSE (language use in an interactive context)				
Establishing of topic (does the speaker clearly introduce their target topic?)	1	2	3	<input type="checkbox"/>
Topic relevance (as based on context and/or prompt)	1	2	3	<input type="checkbox"/>
Inclusion of story grammar elements (characters/agents, setting, actions, resolutions, and more)	1	2	3	<input type="checkbox"/>
Cohesion and coherence (logical flow of utterances and ideas)	1	2	3	<input type="checkbox"/>
Efficiency (how long does it take the speaker to communicate an intended idea using any modality?)	1	2	3	<input type="checkbox"/>
Functional success in interaction (success and efficacy in communicating an intended message based on typical daily activities; multiple should be used for scoring) <i>Examples:</i> 1) How would you order your typical meal at your favorite restaurant? 2) Please show me how you'd respond to an email or a text message from a friend. 3) Can you explain to me what's troubling you about your language?	1	2	3	<input type="checkbox"/>
TOTAL				
Clinician-observed:				
Patient-reported:				
COGNITIVE CONTROL (contributions of non-linguistic cognitive functions to communication)				
Initiation (purposeful and independent initiation of communicative participation)	1	2	3	<input type="checkbox"/>
Inhibition (purposeful, voluntary restraint and adherence to expectations and sharing of content)	1	2	3	<input type="checkbox"/>

Perception (identification and processing of relevant stimuli in immediate environment)	1	2	3	<input type="checkbox"/>
Selective attention (attention to conversation partner and tasks)	1	2	3	<input type="checkbox"/>
Sustained attention (maintenance of attention to conversation partner and tasks in this context)	1	2	3	<input type="checkbox"/>
Working memory (maintenance and use of information provided in and relevant to current context)	1	2	3	<input type="checkbox"/>
Long-term memory (maintenance, retrieval, and use of information prior to current context)	1	2	3	<input type="checkbox"/>
TOTAL				
<i>Clinician-observed:</i>				
 <i>Patient-reported:</i>				
SOCIAL-PRAGMATICS (social participation, engagement, and appropriateness)				
Participation in communicative context (engagement and initiation in communication, including but not limited to responding to the clinician, conversational turn-taking, and initiating topics or ideas)	1	2	3	<input type="checkbox"/>
Initiation of communication repair strategies (independent implementation of strategies to smooth over communication breakdowns)	1	2	3	<input type="checkbox"/>
Use of communication repair strategies when provided support (supported implementation of strategies to smooth over communication breakdowns)	1	2	3	<input type="checkbox"/>
Social appropriateness of communication or participation (including but not limited to mirroring body language, maintaining expected comportment and engagement with clinician)	1	2	3	<input type="checkbox"/>
Empathy or sensitivity to communication partner (recognition and responsiveness to clinician as a human and in terms of topic content)	1	2	3	<input type="checkbox"/>
Use of body to explain or refer to objects, events, and actions (use of gestures, enactments, or visualizations to communicate intended meaning)	1	2	3	<input type="checkbox"/>
Use of facial expression to enhance communication (use of facial expressions to communicate emotional state or feelings about content of a topic or situation)	1	2	3	<input type="checkbox"/>
Use of prosody and intonation to enhance communicative intent (pitch and timing cues to indicate emotion, (dis)agreement, or grammatical content)	1	2	3	<input type="checkbox"/>
Use of communication support to enhance communication (support is defined as AAC, writing, drawing, pointing to objects, objects, low and high tech (including but not limited to pictures, word books, and smart phones); also evaluate the strategic competence in	1	2	3	<input type="checkbox"/>

flexibly switching between communication modalities to communicate an intended message)				
TOTAL				
<i>Clinician-observed:</i>				
<i>Patient-reported:</i>				

307

308 **2.4.3 Statistical Analysis**

309 These analyses are exploratory, with the goals of (1) understanding the
310 assessment items so that a future grant proposal can make any necessary improvements,
311 and (2) generating hypotheses for that project. To assess inter-rater item reliability, we
312 will use the version of the kappa statistic that allows for different sets of raters.
313 Thresholds for acceptable kappa values vary, but we will consider a kappa of 0.60 to be
314 usable [41]. We are also aware of the “kappa paradox” that can arrive if a rater has low
315 sensitivity or specificity. Future work may involve forming summary measures for the
316 subdomains once items have been finalized. Qualitative feedback from the “Think
317 Aloud” procedure will be coded using Dedoose qualitative analytic software [31] by
318 study team members trained in qualitative analysis. This round of coding will apply a
319 fixed code for each FCC item discussed. Then, using the Grounded Theory-based
320 “memo-ing” process [32], three analysts will each independently review the feedback
321 associated with each FCC item, and draft a memo outlining issues/themes/concerns for
322 each. Analysts will subsequently meet to share and reconcile differences in interpretation
323 and achieve consensus regarding thematic content at the item level. The resulting final,
324 integrated memo will inform finalization of the FCC. The FCC is a formative measure

325 rather than assessing a latent trait, so a weighted score may or may not be advisable,
326 depending on how well the items correlate with each other and with overall function; for
327 certain individuals, strength in one item may be a prominent feature of FC, independent
328 of the presence or absence of other strengths.

329 **2.5 Protection of Human Participants**

330 **2.5.1 Participants of Phase 1, Tool Implementation**

331 Our goal for the proposed research is to recruit and enroll 9-10 individuals with a
332 diagnosis of PPA. The majority of individuals evaluated annually as part of the Clinical
333 Core program at the UW ADRC have also consented to being approached for additional
334 research studies. Participants eligible for the study will be patients who have received a
335 diagnosis of PPA by a neurologist (KDR), enrolled in the ADRC Clinical Core or UW
336 Memory and Brain Wellness Registry, and are able to comply with the experimental
337 protocol. Patients who cannot comply with the experimental protocol due to hearing,
338 English proficiency, vision, or cognitive impairment will be excluded. Similarly, patients
339 who do not consent to being video-recorded and having these recordings shared on UW
340 Sharepoint for educational purposes, accessible through the UW ADRC website, will also
341 be excluded.

342 Participants who respond positively to recruitment will be given a full explanation
343 of the project by study staff. Per NIH policy, as a part of the informed consent process,
344 we will also collect contact and demographic information from each of our PPA and
345 control participants. Informed consent will be obtained from all people participating in
346 this study, and all methods of recruitment and experimental protocols will be approved by
347 the institutional review board of the University of Washington. Consent will be obtained

348 from the participant or their legal representative, where the participant would at a
349 minimum provide assent. A copy of the signed consent form will be provided to all
350 enrollees.

351 **2.5.2 Participants of Phases 3 and 4, Tool Development and Phase 2, Tool** 352 **Implementation**

353 Our goal is to also recruit at least 65 SLPs with either expertise in PPA or general
354 knowledge in the assessment and care of adult populations. These SLPs will be recruited
355 through the University of Washington, national and international working groups, and
356 through online forums geared towards this target population. Exclusionary criteria will
357 include inability to commit to the time required for the experimental protocols for an
358 online survey (Phases 3 and 4, Tool Development) as well as dissent to being recorded
359 for those participating in Zoom videoconferencing calls (Phase 2, Tool Implementation).
360 The participant will be recruited through advertisement materials posted online and
361 through physical flyers. Each eligible participant will be provided with information
362 describing the purpose of the project, the experimental procedures, potential risks, and
363 benefits, and required time commitment. If the participant would like to participate, they
364 will receive an email to with an attachment for the informed consent documentation.
365 Each participant will receive a copy of the signed informed consent document, and the
366 original will be retained by the PI and stored on a secured Drive in Co-Investigator
367 KDR's lab.

368 **2.5.3 Protection of Participant Data**

369 Participant information as well as behavioral data will be collected according to
370 the procedures described within **Materials and Methods**. The data will consist of

371 clinical assessments as well as acoustic signals and digital video recorded during study
372 visits. Participant information, such as participant histories and clinical assessments, will
373 be recorded by entering the data directly into an electronic data capture system. The
374 system used will be a secure, HIPAA compliant implementation of the REDCap
375 Research electronic data capture software, hosted by the UW ADRC. This web-based
376 data capture system is designed specifically for human participants research, and is used
377 by over 1,000 institutions worldwide. It provides audit trails for tracking data
378 manipulation and user activity. Access is controlled by a secure web authentication
379 system and SSL encryption, and will be limited to the PI, Co-Investigators, and other
380 IRB-approved study staff only. Behavioral language data will be stored here. The digital
381 video recorded during the study will be stored on a secure, password-protected drive
382 hosted by the UW Sharepoint. Access to study data on this drive will be limited to
383 approved and verified individuals. Paper records will be accessible only to the Co-
384 Investigator, PI and IRB-approved study staff. Participant-identifiable information such
385 as the master list matching participant names to ID numbers will be stored for 5 years and
386 then destroyed. To maintain confidentiality of the participants and their records,
387 participants will be identified in all study records and computer files by a three-digit
388 sequential numeric code.

389 The master list matching participant names to ID numbers will be stored in a
390 password-protected and encrypted digital file that is only accessible to study staff. The
391 privacy and confidentiality of participants participating in this study will be protected at
392 all times. Study procedures, including the explanation of the study and informed consent
393 process, will take place in a private office space. Participants will be referred to

394 throughout study files only by an anonymized numerical code. All computer files
395 containing participant-identifiable information will be kept in secure, access-restricted,
396 encrypted digital storage; any physical files pertaining to study participants will be kept
397 locked in a file cabinet in the Co-Investigator's (KDR) lab. Only IRB-approved study
398 staff will have access to review study records. No sensitive information will be collected
399 during this study that would require reporting to state or local authorities.

400 **2.5.4 Potential Risks**

401 The potential risks to participants from participating in this research are minimal.
402 All participants participating in Phase 1 of Tool Implementation will complete behavioral
403 assessments at a single timepoint. However, the extent of potential fatigue is not beyond
404 what may be experienced in any other daily activity. There is a potential risk for
405 discomfort due to the physical environment of being tested in a private room while being
406 recorded. To preempt this, all participants will receive ample transition time to the space
407 to help them get comfortable and to prepare them for the actual assessment.

408 **2.5.5 Protections Against Risks**

409 All information about the participants will be kept confidential. To maintain
410 confidentiality of the participants and their records, each participant will be assigned an
411 identification number and referred to by this number. The master list matching participant
412 names to ID numbers will be stored in a locked cabinet that is only accessible to the PI
413 and Co-Sponsor. Only IRB-approved study staff will have access to the data. The records
414 will be kept for approximately 5 years after completion of the study. This period will be
415 needed to verify results prior to publication. The PI will be responsible for applying for
416 and maintaining full IRB approval. In addition, all project personnel will be required to

417 complete human participants training. The University of Washington’s Federal-Wide
418 Assurance requires that all University of Washington research with human participants,
419 regardless of funding source, abide by the Belmont principles of respect, beneficence,
420 and justice and the federal regulations in 45 CFR 46. Further, it states that University of
421 Washington will provide initial and continuing education to personnel conducting
422 research with human participants to help ensure that these ethical standards are met. To
423 assist in this process, University of Washington has subscribed to the Consortium for IRB
424 Training Initiative in Human Subjects Protections (CITI).

425 To be certified for human participant research, key project personnel must
426 complete the CITI tutorial every three years; this training must be supplemented annually
427 through CITI refresher tutorials or through attendance at one or more educational
428 sessions held by the IRB. Records verifying the completion of the above training for all
429 individuals will be maintained by Co-Investigators KDR and PKC. Participants in Phase
430 1 of Tool Implementation will be closely monitored by study staff during the study for
431 fatigue, discomfort, or any other adverse events. The PI will be responsible for the
432 reporting of any adverse events that occur over the course of the study. Adverse event
433 reporting will be done according to the guidelines of the University of Washington’s
434 Human Subjects Division and our IRB. All major and minor adverse events will be
435 reported to the IRB. Should a participant express or show signs of discomfort or fatigue
436 that cannot be resolved with short periods of rest, the protocol will be terminated. No
437 special precautions are required before, during or after the study by the participant.

438 **2.5.6 Potential Benefits of the Proposed Research to Human Participants and**
439 **Others**

440 For participants with PPA, we will provide information regarding the results of all
441 testing at the individual's request. This information may be useful for documenting
442 symptom progression and further explanation of their impact on daily participation and
443 communication.

444 **3 Results**

445 This study was approved for funding from the University of Washington's ADRC
446 in February 2024 following internal and external peer review (Awardee: JG, ADRC P30
447 grant, PI: Thomas J. Grabowski, MD). Phase One of Tool Development commenced
448 February 21st, 2024. The results of the data analyses are expected to be available by
449 August 2025.

450 **3.1 Dissemination**

451 The authors will disseminate the results of this multitiered work through academic
452 and clinical conferences and peer-reviewed scientific journals. Results will also be
453 disseminated via stakeholder forums, including the monthly online Memory and Brain
454 Wellness newsletter and PPA Together! Support group. The authors will also develop
455 opportunities to disseminate outcomes of the study to people living with PPA, SLPs, and
456 researchers in collaboration with the National Aphasia Association PPA Task Force and
457 supported by the International SLT/P PPA Network.

458 459 **4 Discussion**

460 To date, there are no standard training materials that enable SLPs to develop
461 clinical expertise in PPA, nor frameworks to communicate assessment findings across
462 health professions, particularly as they pertain to FC ability. In this project, we propose to
463 develop a composite measure of FC that is structured as a simple rating scale and allows
464

465 clinicians to use a common framework to synthesize speech, language, and
466 communication function – regardless of the exact measurement tools used. Our aims are
467 two-fold, to improve both clinical and research practices of PPA assessment. Clear and
468 consistent agreement in behavioral ratings is paramount for appropriate clinical trial
469 recruitment, the implementation of therapeutic intervention, and monitoring change over
470 time. We will develop a series of tools that serve to train clinicians to assess PPA in
471 speakers from an informative participant sample, and to create a validated assessment
472 procedure to assess functional communication, which in turn provides the basis for
473 researcher, practitioner, patient, and care partner education. The outcomes of this work
474 will result in novel educational tools to cultivate comprehensive and resilience-oriented
475 assessment processes, as well as stakeholder tools to provide direct feedback to PwPPA.
476 Moreover, validation of the FC assessment will enhance collaboration and partnership
477 amongst healthcare providers and across institutions that serve this population.

478 **5 Acknowledgements**

479 This work is supported by the generous University of Washington’s Alzheimer’s
480 Disease Research Center Development Project Award (Awardee: JG).

481 **6 Author Contributions**

482 **Conceptualization:** Jeanne Gallée, Paul K. Crane, Kimiko Domoto-Reilly, Rob J.
483 Fredericksen

484 **Data curation:** Jeanne Gallée, Paul K. Crane, Kimiko Domoto-Reilly, Rob J.
485 Fredericksen

486 **Funding acquisition:** Jeanne Gallée

487 **Methodology:** Jeanne Gallée, Paul K. Crane, Kimiko Domoto-Reilly, Rob J.

488 Fredericksen, Aimee Mooney, Jade Cartwright, Maya L. Henry, Brielle C. Stark, Anna

489 Volkmer

490 **Investigation:** Jeanne Gallée, Paul K. Crane, Kimiko Domoto-Reilly, Rob J.

491 Fredericksen, Aimee Mooney, Jade Cartwright, Maya L. Henry, Brielle C. Stark, Anna

492 Volkmer

493 **Formal Analysis:** Jeanne Gallée, Paul K. Crane, Kimiko Domoto-Reilly, Rob J.

494 Fredericksen

495 **Supervision:** Jeanne Gallée, Paul K. Crane, Kimiko Domoto-Reilly, Rob J. Fredericksen

496 **Writing – original draft:** Jeanne Gallée

497 **Writing – review & editing:** Jeanne Gallée, Paul K. Crane, Kimiko Domoto-Reilly, Rob

498 J. Fredericksen, Aimee Mooney, Jade Cartwright, Maya L. Henry, Brielle C. Stark, Anna

499 Volkmer

500 **References**

501 1. What Is Frontotemporal Dementia, the Disease Bruce Willis Is Diagnosed With? |

502 AFTD [Internet]. 2023 [cited 2024 Feb 20]. Available from:

503 <https://www.theaftd.org/posts/all-us-states/what-is-frontotemporal-dementia-the->

504 [disease-bruce-willis-is-diagnosed-with/](https://www.theaftd.org/posts/all-us-states/what-is-frontotemporal-dementia-the-disease-bruce-willis-is-diagnosed-with/)

505 2. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et

506 al. Classification of primary progressive aphasia and its variants. *Neurology*. 2011

507 Mar 15;76(11):1006–14.

- 508 3. Marshall CR, Hardy CJD, Volkmer A, Russell LL, Bond RL, Fletcher PD, et al.
509 Primary progressive aphasia: a clinical approach. *J Neurol*. 2018
510 Jun;265(6):1474–90.
- 511 4. Ruksenaite J, Volkmer A, Jiang J, Johnson JC, Marshall CR, Warren JD, et al.
512 Primary Progressive Aphasia: Toward a Pathophysiological Synthesis. *Curr*
513 *Neurol Neurosci Rep*. 2021 Feb 4;21(3):7.
- 514 5. Belder CRS, Marshall CR, Jiang J, Mazzeo S, Chokesuwattanaskul A, Rohrer JD,
515 et al. Primary progressive aphasia: six questions in search of an answer. *J Neurol*.
516 2024 Feb;271(2):1028–46.
- 517 6. Ramsberger G, Rende B. Measuring transactional success in the conversation of
518 people with aphasia. *Aphasiology*. 2002 Mar 1;16(3):337–53.
- 519 7. Doedens WJ, Meteyard L. What is Functional Communication? A Theoretical
520 Framework for Real-World Communication Applied to Aphasia Rehabilitation.
521 *Neuropsychol Rev*. 2022 Dec;32(4):937–73.
- 522 8. Volkmer A, Cartwright J, Ruggero L, Beales A, Gallée J, Grasso S, Henry M,
523 Jokel R, Kindell J, Khayum R, Pozzebon M. Principles and philosophies for
524 speech and language therapists working with people with primary progressive
525 aphasia: An international expert consensus. *Disability and Rehabilitation*. 2023
526 Mar 13;45(6):1063-78.
- 527 9. Kim SK, Park M. Effectiveness of person-centered care on people with
528 dementia: a systematic review and meta-analysis. *Clinical Interventions in*
529 *Aging*. 2017 Feb 17;12:381–97.


- 530 10. Hardy CJD, Taylor-Rubin C, Taylor B, Harding E, Gonzalez AS, Jiang J, et al.
531 Symptom-led staging for semantic and non-fluent/agrammatic variants of
532 primary progressive aphasia. *Alzheimer's & Dementia*. 2024;20(1):195–210.
- 533 11. Gallée J, Cartwright J, Volkmer A, Whitworth A, Hersh D. “Please Don’t Assess
534 Him to Destruction”: The R.A.I.S.E. Assessment Framework for Primary
535 Progressive Aphasia. *Am J Speech Lang Pathol*. 2023 Mar 9;32(2):391–410.
- 536 12. Fazio S, Pace D, Flinner J, Kallmyer B. The Fundamentals of Person-Centered
537 Care for Individuals With Dementia. *The Gerontologist*. 2018 Jan
538 18;58(suppl_1):S10–9.
- 539 13. Krein L, Jeon YH, Amberber AM, Fethney J. The Assessment of Language and
540 Communication in Dementia: A Synthesis of Evidence. *Am J Geriatr Psychiatry*.
541 2019 Apr;27(4):363–77.
- 542 14. Ho T, Whitworth A, Hersh D, Cartwright J. “They are dealing with people’s
543 lives...”: Diagnostic and post-diagnostic healthcare experiences in primary
544 progressive aphasia. *International Journal of Speech-Language Pathology*. 2023
545 May 4;25(3):449–61.
- 546 15. Suárez-González A, Cassani A, Gopalan R, Stott J, Savage S. When it is not
547 primary progressive aphasia: A scoping review of spoken language impairment in
548 other neurodegenerative dementias. *Alzheimer's & Dementia: Translational
549 Research & Clinical Interventions*. 2021;7(1):e12205.
- 550 16. COMET Initiative | Primary Progressive Aphasia: a Core Outcome Set for
551 improving intervention research [Internet]. [cited 2024 Mar 11]. Available from:
552 <https://www.comet-initiative.org/Studies/Details/1871>

- 553 17. Gallée J, Volkmer A. A Window Into Functional Communication: Leveraging
554 Naturalistic Speech Samples in Primary Progressive Aphasia. *Perspect ASHA*
555 *SIGs*. 2021 Aug 20;6(4):704–13.
- 556 18. Kirshner B, Guyatt G. A methodological framework for assessing health indices.
557 *J Chronic Dis*. 1985;38(1):27–36.
- 558 19. Hersh D, Boud D. Reassessing assessment: what can post stroke aphasia
559 assessment learn from research on assessment in education? *Aphasiology*. 2024
560 Jan 2;38(1):123–43.
- 561 20. Buntinx WH. Understanding disability: A strengths-based approach. *The Oxford*
562 *handbook of positive psychology and disability*. 2013 Aug 22:7-18.
- 563 21. Patel N, Peterson KA, Ingram RU, Storey I, Cappa SF, Catricala E, et al. A
564 ‘Mini Linguistic State Examination’ to classify primary progressive aphasia.
565 *Brain Communications*. 2022 Apr 1;4(2):fcab299.
- 566 22. Matias-Guiu JA, Grasso SM. Primary progressive aphasia: in search of brief
567 cognitive assessments. *Brain Communications*. 2022 Oct 1;4(5):fcac227.
- 568 23. Sapolsky D, Domoto-Reilly K, Dickerson BC. Use of the Progressive Aphasia
569 Severity Scale (PASS) in monitoring speech and language status in PPA.
570 *Aphasiology*. 2014 Sep 2;28(8–9):993–1003.
- 571 24. McGee JS, McElroy M, Meraz R, Myers DR. A qualitative analysis of virtues
572 and strengths in persons living with early stage dementia informed by the values
573 in action framework. *Dementia*. 2023 Jan 1;22(1):46–67.
- 574 25. Loizidou M, Brotherhood E, Harding E, Crutch S, Warren JD, Hardy CJD, et al.
575 ‘Like going into a chocolate shop, blindfolded’: What do people with primary

- 576 progressive aphasia want from speech and language therapy? International
577 Journal of Language & Communication Disorders. 2023;58(3):737–55.
- 578 26. Jünger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on Conducting
579 and REporting DELphi Studies (CREDES) in palliative care: Recommendations
580 based on a methodological systematic review. Palliative medicine. 2017
581 Sep;31(8):684-706.
- 582 27. Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: How to
583 decide its appropriateness. World J Methodol. 2021 Jul 20;11(4):116–29.
- 584 28. Beiderbeck D, Frevel N, von der Gracht HA, Schmidt SL, Schweitzer VM.
585 Preparing, conducting, and analyzing Delphi surveys: Cross-disciplinary
586 practices, new directions, and advancements. MethodsX. 2021 Jan 1;8:101401.
- 587 29. Qualtrics [Internet]. [cited 2024 Mar 4]. Qualtrics XM - Experience Management
588 Software. Available from: <https://www.qualtrics.com/>
- 589 30. Mauksch S, von der Gracht HA, Gordon TJ. Who is an expert for foresight? A
590 review of identification methods. Technological Forecasting and Social Change.
591 2020 May 1;154:119982.
- 592 31. Sociocultural Research Consultants LLC. (2023). Dedoose v.9.0.90. Retrieved
593 from www.dedoose.com. www.dedoose.com
- 594 32. Corbin J, Strauss A. Grounded theory methodology. Handbook of qualitative
595 research. 1994;17:273-85.
- 596 33. The International Speech and Language Therapy / Pathology Primary
597 Progressive Aphasia Network [Internet]. [cited 2024 Feb 20]. Available from:
598 <https://speechtherapyppa.builtbyknights.com/>

- 599 34. Morris JC. Clinical Dementia Rating: A Reliable and Valid Diagnostic and
600 Staging Measure for Dementia of the Alzheimer Type. International
601 Psychogeriatrics. 1997 Dec;9(S1):173–6.
- 602 35. Morris JC, Ernesto C, Schafer K, Coats M, Leon S, Sano M, Thal LJ, Woodbury
603 P. The Alzheimer's Disease Cooperative Study. Clinical Dementia Rating
604 training and reliability in multi-center studies: The Alzheimer's Disease
605 Cooperative Study Experience. Neurology. 1997;48:1508-10.
- 606 36. Wilson SM, Eriksson DK, Schneck SM, Lucanie JM. A quick aphasia battery for
607 efficient, reliable, and multidimensional assessment of language function. Jäncke
608 L, editor. PLoS ONE. 2018 Feb 9;13(2):e0192773.
- 609 37. Swinburn K, Best W, Beeke S, Cruice M, Smith L, Pearce Willis E, et al. A
610 concise patient reported outcome measure for people with aphasia: the aphasia
611 impact questionnaire 21. Aphasiology. 2019 Sep 2;33(9):1035–60.
- 612 38. Ericsson KA, Simon HA. Protocol analysis: Verbal reports as data (Rev. ed.).
613 Cambridge, MA: Bradford. 1993.
- 614 39. Wolcott MD, Lobczowski NG. Using cognitive interviews and think-aloud
615 protocols to understand thought processes. Currents in Pharmacy Teaching and
616 Learning. 2021 Feb 1;13(2):181–8.
- 617 40. ParticiPics – Aphasia Institute [Internet]. [cited 2024 Feb 20]. Available from:
618 <https://www.aphasia.ca/participics/>
- 619 41. McHugh ML. Interrater reliability: the kappa statistic. Biochemia Medica. 2012
620 Oct 15;22(3):276–82.

1. Development



2. Implementation




Figure 1